

Univercells expands into the United States with new offices in Andover, MA

27 September 2023 | News

The company continues to deliver on the commitment to bring innovative and cost-effective technologies to the global market to make biologics more accessible



Univercells, a Belgian biotechnology company dedicated to ensuring that everyone has access to biologics everywhere in the world, is pleased to announce the opening of the first United States (US) offices for the group. Located in Andover, Massachusetts, the office is already up and running, and features a showroom with Ntensify™ mRNA production technologies from portfolio company, [Quantoom Biosciences](#). A launch event is being held on the day of release, September 26, 2023, and the location will then be accessible to customers and prospects as of October 2023.

“Since the inception of Univercells in Brussels, Belgium in 2013, we have been vocal about wanting to expand into the United States. With customers, shareholders and investors already based in the US, this expansion allows our Group to leverage our strong proprietary infrastructure via the Belgium sites here in Andover to deepen those relationships,” said **Hugues Bultot**, Co-Founder and CEO of Univercells. “We are thrilled to see these plans come to fruition and to bring our technologies, CDMO and advisory services across the border with an office and labs that allow us to highlight the different affiliates within the Group. So far, we have received tremendous support and excitement from existing shareholders, academia, and customers, which makes us confident and enthusiastic for the future.”

The new office and lab space is located at Andover Park. The site was recently redeveloped by Celera Properties and True North Management Group into a cutting-edge hub for life-science innovation. Univercells Group has a total of 800 sqm of offices and labs, ready to welcome new colleagues. The US branch is growing rapidly and is actively recruiting scientific and commercial profiles to expand its headcount.

“Our goal is to be a critical partner to customers that need high quality and reliable support for complex viral vector and nucleic acid projects quickly and cost-efficiently. But understandably, prospects and investors can see challenges with doing business across a global border,” **José Castillo**, Co-Founder and CEO of Quantoom Biosciences continued. “Now being in Andover, just a short drive from Boston, we are strategically positioned within this emerging hub for

biomanufacturing, contract research, medical device and other diverse life science and innovation industry companies. The local presence enables us to be even more proactive in creating tailor-made solutions for American clients, as well as making new connections globally.”

[Univercells](#) is an expanding campus of interconnected biotechnology companies with each company focused on solving a different challenge in meeting global demand for bioproduction. [Quantoom Biosciences](#) is at the forefront of developing disruptive mRNA production technologies that are meticulously designed to deliver high-performance results while maintaining a minimal footprint and cost-effectiveness. [Exothera](#) is a contract development and manufacturing organization (CDMO) focused on viral vector and nucleic acid support. [Unizima](#) offers business advisory services for emerging players seeking global expansion, and [RLM Consulting](#) delivers regulatory advisory support in Europe and the US.

With the new the Andover site, Univercells now has offices in the United States, France and India, in addition to the flagship offices in Belgium.